A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes.
Journal Article (Clinical Trial;Journal Article)
BACKGROUND: The acute benefits of platelet glycoprotein IIb/IIIa inhibitors for non-ST-segment elevation acute coronary syndromes (NSTE ACS) remain unclear. METHODS: In this pilot trial, 311 patients with NSTE ACS were randomly assigned in the emergency department to double-blinded therapy with eptifibatide or placebo for 12 to 24 hours before crossover to open-label eptifibatide. Serial creatine-kinase MB (CK-MB) and quantitative cardiac troponin T levels were collected during the first 24 hours to assess the impact of early platelet glycoprotein IIb/IIIa blockade on infarct size as measured by cardiac markers. RESULTS: Median peak CK-MB (10.3 vs 11.8 ng/mL; P =.71) and peak quantitative cardiac troponin T levels (0.2 vs 0.3 ng/mL; P =.95) were similar between treatment groups, respectively. Median calculated peak CK-MB values (41 vs 40 ng/mL; P =.72) and area under the CK-MB curve measurements (980 vs 764 microg/min/L; P =.68) from curve-fitting analyses that could be performed in 106 of 311 patients were also similar. CONCLUSIONS: In this pilot trial, early administration of eptifibatide in the emergency department did not modulate serologic measurements of infarct size in patients with NSTE ACS.
- Roe, MT; Christenson, RH; Ohman, EM; Bahr, R; Fesmire, FM; Storrow, A; Mollod, M; Peacock, WF; Rosenblatt, JA; Yang, H; Fraulo, ES; Hoekstra, JW; Gibler, WB; EARLY Investigators, ; Emergency Medicine Cardiac Research and Education Group,
- December 2003
Volume / Issue
- 146 / 6
Start / End Page
- 993 - 998
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)
- United States